Linked Life Data

12086555

Source:http://linkedlifedata.com/resource/pubmed/id/12086555

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12086555rdf:typepubmed:Citationlld:pubmed
pubmed-article:12086555lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:12086555lifeskim:mentionsumls-concept:C0003873lld:lifeskim
pubmed-article:12086555lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:12086555lifeskim:mentionsumls-concept:C0245109lld:lifeskim
pubmed-article:12086555pubmed:issue7-8lld:pubmed
pubmed-article:12086555pubmed:dateCreated2002-6-27lld:pubmed
pubmed-article:12086555pubmed:abstractTextTo summarize the safety data arising from clinical trials of anakinra, a human recombinant form of interleukin-1 receptor antagonist (IL-1Ra) developed for the treatment of rheumatoid arthritis (RA).lld:pubmed
pubmed-article:12086555pubmed:languageenglld:pubmed
pubmed-article:12086555pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12086555pubmed:citationSubsetIMlld:pubmed
pubmed-article:12086555pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12086555pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12086555pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12086555pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12086555pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12086555pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12086555pubmed:statusMEDLINElld:pubmed
pubmed-article:12086555pubmed:issn1060-0280lld:pubmed
pubmed-article:12086555pubmed:authorpubmed-author:CalabreseLeon...lld:pubmed
pubmed-article:12086555pubmed:issnTypePrintlld:pubmed
pubmed-article:12086555pubmed:volume36lld:pubmed
pubmed-article:12086555pubmed:ownerNLMlld:pubmed
pubmed-article:12086555pubmed:authorsCompleteYlld:pubmed
pubmed-article:12086555pubmed:pagination1204-9lld:pubmed
pubmed-article:12086555pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:12086555pubmed:meshHeadingpubmed-meshheading:12086555...lld:pubmed
pubmed-article:12086555pubmed:meshHeadingpubmed-meshheading:12086555...lld:pubmed
pubmed-article:12086555pubmed:meshHeadingpubmed-meshheading:12086555...lld:pubmed
pubmed-article:12086555pubmed:meshHeadingpubmed-meshheading:12086555...lld:pubmed
pubmed-article:12086555pubmed:meshHeadingpubmed-meshheading:12086555...lld:pubmed
pubmed-article:12086555pubmed:meshHeadingpubmed-meshheading:12086555...lld:pubmed
pubmed-article:12086555pubmed:meshHeadingpubmed-meshheading:12086555...lld:pubmed
pubmed-article:12086555pubmed:meshHeadingpubmed-meshheading:12086555...lld:pubmed
pubmed-article:12086555pubmed:meshHeadingpubmed-meshheading:12086555...lld:pubmed
pubmed-article:12086555pubmed:meshHeadingpubmed-meshheading:12086555...lld:pubmed
pubmed-article:12086555pubmed:articleTitleAnakinra treatment of patients with rheumatoid arthritis.lld:pubmed
pubmed-article:12086555pubmed:affiliationDepartment of Rheumatic & Immunologic Diseases, Cleveland, OH, USA. calabri@cesmtp.ccf.orglld:pubmed
pubmed-article:12086555pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12086555pubmed:publicationTypeReviewlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12086555lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12086555lld:pubmed